Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Camidge, D. Ross; Gadgeel, Shirish; Ou, Sai-Hong; Gandhi, Leena; Riely, Gregory; Cetnar, Jeremy; West, Howard; Socinski, Mark; Chiappori, Alberto; Mekhail, Tarek; Chao, Bo; Borghaei, Hossein; Gold, Kathryn; Bordogna, Walter; Balas, Bogdana; Noe, Johannes; Golding, Sophie; Zeaiter, Ali; Shaw, Alice

authors

Publication Date

  • January 1, 2017

webpage

published in

category

keywords

  • ALK-inhibitor
  • Alectinib
  • NSCLC
  • US

start page

  • S378

end page

  • S378

volume

  • 12

issue

  • 1